The elderly and direct antiviral agents: Constraint or challenge?
Direct antiviral agents (DAAs) for chronic hepatitis C showed great effectiveness and good safety profile. So far, few data are available about their use in elderly subjects. To assess management, safety and outcome of DAAs treatments in the elderly. This retrospective, single-centre study enrolled...
Saved in:
| Published in | Digestive and liver disease Vol. 49; no. 9; pp. 1036 - 1042 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
01.09.2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1590-8658 1878-3562 1878-3562 |
| DOI | 10.1016/j.dld.2017.05.019 |
Cover
Loading…
| Abstract | Direct antiviral agents (DAAs) for chronic hepatitis C showed great effectiveness and good safety profile. So far, few data are available about their use in elderly subjects.
To assess management, safety and outcome of DAAs treatments in the elderly.
This retrospective, single-centre study enrolled all patients aged ≥65 years, compared by age (group A: 65–74 years, group B: ≥75 years), who completed DAAs between February 2015–November 2016. Variables potentially associated to adverse events (AEs) were analyzed. Sustained virological response (SVR) was evaluated at 12-weeks follow-up.
DAAs were administered to 221 patients aged ≥65 years (males: 112; group A: 130, group B: 91). Prescribed regimens were: sofosbuvir-based: 44 patients (19.9%), simeprevir-based: 25 (15%), ledipasvir-based: 49 (22.2%), daclatasvir-based: 12 (5.4%), paritaprevir/ritonavir+ombitasvir±dasabuvir: 91 (41.2%). Ribavirin was used in 121 patients. In 58 subjects co-medications were adjusted due to drug interactions. At least one AE occurred in 130 patients, including 13 SAEs, mainly in older subjects (p=0.04). Female sex (p=0.04), liver stiffness (p=0.023), use of simeprevir (p=0.03) and ribavirin (p=0.009) were associated with AEs. SVR-12 was achieved in 96,9% of subjects.
A careful baseline evaluation and a strict monitoring allow to optimise management and outcome of DAAs in elderly. |
|---|---|
| AbstractList | Direct antiviral agents (DAAs) for chronic hepatitis C showed great effectiveness and good safety profile. So far, few data are available about their use in elderly subjects.
To assess management, safety and outcome of DAAs treatments in the elderly.
This retrospective, single-centre study enrolled all patients aged ≥65 years, compared by age (group A: 65–74 years, group B: ≥75 years), who completed DAAs between February 2015–November 2016. Variables potentially associated to adverse events (AEs) were analyzed. Sustained virological response (SVR) was evaluated at 12-weeks follow-up.
DAAs were administered to 221 patients aged ≥65 years (males: 112; group A: 130, group B: 91). Prescribed regimens were: sofosbuvir-based: 44 patients (19.9%), simeprevir-based: 25 (15%), ledipasvir-based: 49 (22.2%), daclatasvir-based: 12 (5.4%), paritaprevir/ritonavir+ombitasvir±dasabuvir: 91 (41.2%). Ribavirin was used in 121 patients. In 58 subjects co-medications were adjusted due to drug interactions. At least one AE occurred in 130 patients, including 13 SAEs, mainly in older subjects (p=0.04). Female sex (p=0.04), liver stiffness (p=0.023), use of simeprevir (p=0.03) and ribavirin (p=0.009) were associated with AEs. SVR-12 was achieved in 96,9% of subjects.
A careful baseline evaluation and a strict monitoring allow to optimise management and outcome of DAAs in elderly. Abstract Background direct antiviral agents (DAAs) for chronic hepatitis C showed great effectiveness and good safety profile. So far, few data are available about their use in elderly subjects. Aim to assess management, safety and outcome of DAAs treatments in the elderly. Methods This retrospective, single-centre study enrolled all patients aged ≥65 years, compared by age (group A: 65-74 years, group B: ≥75 years), who completed DAAs between February 2015-November 2016. Variables potentially associated to adverse events (AEs) were analyzed. Sustained virological response (SVR) was evaluated at 12-weeks follow-up. Results DAAs were administered to 221 patients aged ≥65 years (males: 112; group A: 130, group B: 91). Prescribed regimens were: sofosbuvir-based: 44 patients (19.9%), simeprevir-based: 25 (15%), ledipasvir-based: 49 (22.2%), daclatasvir-based: 12 (5.4%), paritaprevir/ritonavir + ombitasvir ± dasabuvir: 91 (41.2%). Ribavirin was used in 121 patients. In 58 subjects co-medications were adjusted due to drug interactions. At least one AE occurred in 130 patients, including 13 SAEs, mainly in older subjects (p = 0.04). Female sex (p = 0.04), liver stiffness (p = 0.023), use of simeprevir (p = 0.03) and ribavirin (p = 0.009) were associated with AEs. SVR-12 was achieved in 96,9% of subjects. Conclusions A careful baseline evaluation and a strict monitoring allow to optimise management and outcome of DAAs in elderly. Direct antiviral agents (DAAs) for chronic hepatitis C showed great effectiveness and good safety profile. So far, few data are available about their use in elderly subjects.BACKGROUNDDirect antiviral agents (DAAs) for chronic hepatitis C showed great effectiveness and good safety profile. So far, few data are available about their use in elderly subjects.To assess management, safety and outcome of DAAs treatments in the elderly.AIMTo assess management, safety and outcome of DAAs treatments in the elderly.This retrospective, single-centre study enrolled all patients aged ≥65 years, compared by age (group A: 65-74 years, group B: ≥75 years), who completed DAAs between February 2015-November 2016. Variables potentially associated to adverse events (AEs) were analyzed. Sustained virological response (SVR) was evaluated at 12-weeks follow-up.METHODSThis retrospective, single-centre study enrolled all patients aged ≥65 years, compared by age (group A: 65-74 years, group B: ≥75 years), who completed DAAs between February 2015-November 2016. Variables potentially associated to adverse events (AEs) were analyzed. Sustained virological response (SVR) was evaluated at 12-weeks follow-up.DAAs were administered to 221 patients aged ≥65 years (males: 112; group A: 130, group B: 91). Prescribed regimens were: sofosbuvir-based: 44 patients (19.9%), simeprevir-based: 25 (15%), ledipasvir-based: 49 (22.2%), daclatasvir-based: 12 (5.4%), paritaprevir/ritonavir+ombitasvir±dasabuvir: 91 (41.2%). Ribavirin was used in 121 patients. In 58 subjects co-medications were adjusted due to drug interactions. At least one AE occurred in 130 patients, including 13 SAEs, mainly in older subjects (p=0.04). Female sex (p=0.04), liver stiffness (p=0.023), use of simeprevir (p=0.03) and ribavirin (p=0.009) were associated with AEs. SVR-12 was achieved in 96,9% of subjects.RESULTSDAAs were administered to 221 patients aged ≥65 years (males: 112; group A: 130, group B: 91). Prescribed regimens were: sofosbuvir-based: 44 patients (19.9%), simeprevir-based: 25 (15%), ledipasvir-based: 49 (22.2%), daclatasvir-based: 12 (5.4%), paritaprevir/ritonavir+ombitasvir±dasabuvir: 91 (41.2%). Ribavirin was used in 121 patients. In 58 subjects co-medications were adjusted due to drug interactions. At least one AE occurred in 130 patients, including 13 SAEs, mainly in older subjects (p=0.04). Female sex (p=0.04), liver stiffness (p=0.023), use of simeprevir (p=0.03) and ribavirin (p=0.009) were associated with AEs. SVR-12 was achieved in 96,9% of subjects.A careful baseline evaluation and a strict monitoring allow to optimise management and outcome of DAAs in elderly.CONCLUSIONSA careful baseline evaluation and a strict monitoring allow to optimise management and outcome of DAAs in elderly. |
| Author | Fabrizio, Claudia Milano, Eugenio Dell’Acqua, Raffaele Scudeller, Luigia Lo Caputo, Sergio Angarano, Gioacchino Bruno, Giuseppe Monno, Laura Milella, Michele Saracino, Annalisa |
| Author_xml | – sequence: 1 givenname: Claudia surname: Fabrizio fullname: Fabrizio, Claudia email: claudia.fabrizio.82@gmail.com organization: Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy – sequence: 2 givenname: Annalisa surname: Saracino fullname: Saracino, Annalisa organization: Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy – sequence: 3 givenname: Luigia surname: Scudeller fullname: Scudeller, Luigia organization: Scientific Direction, Clinical Epidemiology Unit, IRCCS San Matteo Foundation, Pavia, Italy – sequence: 4 givenname: Eugenio surname: Milano fullname: Milano, Eugenio organization: Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy – sequence: 5 givenname: Raffaele surname: Dell’Acqua fullname: Dell’Acqua, Raffaele organization: Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy – sequence: 6 givenname: Giuseppe surname: Bruno fullname: Bruno, Giuseppe organization: Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy – sequence: 7 givenname: Sergio surname: Lo Caputo fullname: Lo Caputo, Sergio organization: Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy – sequence: 8 givenname: Laura surname: Monno fullname: Monno, Laura organization: Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy – sequence: 9 givenname: Michele surname: Milella fullname: Milella, Michele organization: Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy – sequence: 10 givenname: Gioacchino surname: Angarano fullname: Angarano, Gioacchino organization: Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28651903$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU1vFSEUhompsR_6A9yYWbqZKR8DA5pomhutJk1cWNeEC2darlyowG1y_71MbnXRxLrihLzP4fCcU3QUUwSEXhM8EEzE-WZwwQ0Uk2nAfMBEPUMnRE6yZ1zQo1ZzhXspuDxGp6VsMKZEcPwCHdN2SRRmJ-ji-hY6CA5y2Hcmus75DLa2svp7n03ozA3EWt51qxRLzcbH2qXc2VsTAsQb-PgSPZ9NKPDq4TxDPz5_ul596a--XX5dXVz1duSy9oICnc1EqAAzAQFlnBwBz0xgwRUVyjBYCyuZcQzmtTTMzXK0ayelgzY2O0NvD33vcvq1g1L11hcLIZgIaVc0UWSkUnFJWvTNQ3S33oLTd9lvTd7rP99uAXII2JxKyTD_jRCsF7V6o5tavajVmOumtjHTI8b6aqpPcbESniTfH0hoeu49ZF2sh2jh4Fq75J-kPzyibfDRWxN-wh7KJu1ybN410YVqrL8vS192TiaGpRJja6D-3eA_j_8G_Ly6cw |
| CitedBy_id | crossref_primary_10_1111_jcpt_12744 crossref_primary_10_1002_agm2_12190 crossref_primary_10_4254_wjh_v11_i9_678 crossref_primary_10_1371_journal_pone_0217052 crossref_primary_10_1111_jvh_13679 crossref_primary_10_1007_s41999_019_00167_3 |
| Cites_doi | 10.1111/j.1532-5415.2012.04188.x 10.1016/j.cmi.2016.09.021 10.1007/s12072-015-9684-3 10.1016/j.jhep.2016.09.001 10.1002/jmv.24635 10.2147/CEOR.S108288 10.1371/journal.pone.0157832 10.1016/j.antiviral.2016.10.012 10.1016/j.jhep.2016.11.012 10.1053/j.gastro.2014.03.003 10.1002/hep.23691 10.1080/00365540903095358 10.1016/j.jcv.2017.01.003 10.3748/wjg.v21.i24.7412 10.1111/j.1447-0594.2006.00341.x 10.1002/hep.28137 10.1016/j.jhep.2008.02.008 10.1111/apt.13514 10.1111/jvh.12663 10.1097/MD.0000000000002482 10.1111/jgs.13928 10.1111/jvh.12636 10.1111/liv.13288 10.1016/j.cgh.2016.07.001 10.1111/apt.13769 10.1097/MD.0000000000005143 |
| ContentType | Journal Article |
| Copyright | 2017 Editrice Gastroenterologica Italiana S.r.l. Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2017 Editrice Gastroenterologica Italiana S.r.l. – notice: Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.dld.2017.05.019 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1878-3562 |
| EndPage | 1042 |
| ExternalDocumentID | 28651903 10_1016_j_dld_2017_05_019 S1590865817308964 1_s2_0_S1590865817308964 |
| Genre | Journal Article Observational Study |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FD8 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OC. ON0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SDF SDG SEL SES SEW SPCBC SSH SSZ T5K Z5R ~G- AACTN AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c458t-62e2fa7126ea7e1e9ad84e0f360659269a3eb6c83ad3efb8a3df84cbd88de1653 |
| IEDL.DBID | .~1 |
| ISSN | 1590-8658 1878-3562 |
| IngestDate | Thu Sep 04 22:12:08 EDT 2025 Wed Feb 19 02:41:00 EST 2025 Thu Apr 24 23:07:06 EDT 2025 Tue Jul 01 02:08:13 EDT 2025 Fri Feb 23 02:28:13 EST 2024 Sun Feb 23 10:18:44 EST 2025 Tue Aug 26 19:26:47 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | Antiviral treatment HCV Chronic hepatitis C antiviral treatment chronic hepatitis C |
| Language | English |
| License | Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c458t-62e2fa7126ea7e1e9ad84e0f360659269a3eb6c83ad3efb8a3df84cbd88de1653 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 28651903 |
| PQID | 1914289581 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1914289581 pubmed_primary_28651903 crossref_primary_10_1016_j_dld_2017_05_019 crossref_citationtrail_10_1016_j_dld_2017_05_019 elsevier_sciencedirect_doi_10_1016_j_dld_2017_05_019 elsevier_clinicalkeyesjournals_1_s2_0_S1590865817308964 elsevier_clinicalkey_doi_10_1016_j_dld_2017_05_019 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-01 |
| PublicationDateYYYYMMDD | 2017-09-01 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Digestive and liver disease |
| PublicationTitleAlternate | Dig Liver Dis |
| PublicationYear | 2017 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Toyoda, Kumada, Tada (bib0055) 2017; 66 Bruno, Saracino, Fabrizio (bib0085) 2017; 24 Singh, Bajorek (bib0040) 2014; 12 Maor, Malnick, Melzer (bib0135) 2016; 11 Banerjee, Reddy (bib0130) 2016; 43 Asahina, Tsuchiya, Tamaki (bib0095) 2010; 52 Younossi, Stepanova, Nader (bib0140) 2016; 64 Maan, van Tilborg, Deterding (bib0125) 2016; 14 Rodríguez-Osorio, Cid, Morano (bib0065) 2016; 88 Orimo, Ito, Suzuki (bib0070) 2006; 6 Mariano, Scalia Tomba, Tosti (bib0010) 2009; 41 European Centre for Disease Prevention and Control (bib0005) 2016 Conti, Brillanti, Buonfiglioli (bib0060) 2016; 24 Morisco, Loperto, Stroffolini (bib0105) 2017; 89 Castera, Forns, Alberti (bib0075) 2008; 48 Perrone, Sangiorgi, Buda (bib0110) 2016; 8 European Association for the Study of the Liver (bib0080) 2017; 66 Ickowicz (bib0025) 2012; 60 Gill, Ghazinian, Manch (bib0020) 2016; 10 Pawlotsky (bib0035) 2014; 146 Pellicelli, Pace Palitti, Vignally (bib0045) 2016; 37 Golabi, Otgonsuren, Suen (bib0090) 2016; 95 Fabrizio, Procopio, Scudeller (bib0115) 2017; 23 Ogawa, Furusyo, Nomura (bib0050) 2016; 136 Vespasiani-Gentilucci, Galati, Gallo (bib0015) 2015; 21 Mancusi, Andreoni, d’Angela (bib0100) 2016; 95 Vermehren, Peiffer, Welsch (bib0030) 2016; 44 Soriano, Barreiro, de Mendoza (bib0120) 2016; 63 Maan (10.1016/j.dld.2017.05.019_bib0125) 2016; 14 Bruno (10.1016/j.dld.2017.05.019_bib0085) 2017; 24 Gill (10.1016/j.dld.2017.05.019_bib0020) 2016; 10 European Association for the Study of the Liver (10.1016/j.dld.2017.05.019_bib0080) 2017; 66 Perrone (10.1016/j.dld.2017.05.019_bib0110) 2016; 8 Vespasiani-Gentilucci (10.1016/j.dld.2017.05.019_bib0015) 2015; 21 Singh (10.1016/j.dld.2017.05.019_bib0040) 2014; 12 Orimo (10.1016/j.dld.2017.05.019_bib0070) 2006; 6 Mariano (10.1016/j.dld.2017.05.019_bib0010) 2009; 41 Rodríguez-Osorio (10.1016/j.dld.2017.05.019_bib0065) 2016; 88 Castera (10.1016/j.dld.2017.05.019_bib0075) 2008; 48 Banerjee (10.1016/j.dld.2017.05.019_bib0130) 2016; 43 Ogawa (10.1016/j.dld.2017.05.019_bib0050) 2016; 136 Younossi (10.1016/j.dld.2017.05.019_bib0140) 2016; 64 Pawlotsky (10.1016/j.dld.2017.05.019_bib0035) 2014; 146 Fabrizio (10.1016/j.dld.2017.05.019_bib0115) 2017; 23 Maor (10.1016/j.dld.2017.05.019_bib0135) 2016; 11 Golabi (10.1016/j.dld.2017.05.019_bib0090) 2016; 95 Toyoda (10.1016/j.dld.2017.05.019_bib0055) 2017; 66 Conti (10.1016/j.dld.2017.05.019_bib0060) 2016; 24 Pellicelli (10.1016/j.dld.2017.05.019_bib0045) 2016; 37 Mancusi (10.1016/j.dld.2017.05.019_bib0100) 2016; 95 European Centre for Disease Prevention and Control (10.1016/j.dld.2017.05.019_bib0005) 2016 Asahina (10.1016/j.dld.2017.05.019_bib0095) 2010; 52 Vermehren (10.1016/j.dld.2017.05.019_bib0030) 2016; 44 Morisco (10.1016/j.dld.2017.05.019_bib0105) 2017; 89 Ickowicz (10.1016/j.dld.2017.05.019_bib0025) 2012; 60 Soriano (10.1016/j.dld.2017.05.019_bib0120) 2016; 63 |
| References_xml | – volume: 89 start-page: 291 year: 2017 end-page: 297 ident: bib0105 article-title: Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: tail of a cohort infected in past decades publication-title: J Med Virol – volume: 10 start-page: 415 year: 2016 end-page: 423 ident: bib0020 article-title: Hepatitis C virus as a systemic disease: reaching beyond the liver publication-title: Hepatol Int – volume: 52 start-page: 518 year: 2010 end-page: 527 ident: bib0095 article-title: Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection publication-title: Hepatology – volume: 37 start-page: 653 year: 2016 end-page: 661 ident: bib0045 article-title: Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype-1 elderly cirrhotic patients: a real life study publication-title: Liver Int – volume: 24 start-page: 454 year: 2016 end-page: 463 ident: bib0060 article-title: Safety and efficacy of direct acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older publication-title: J Viral Hepat – volume: 21 start-page: 7412 year: 2015 end-page: 7426 ident: bib0015 article-title: Hepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimens publication-title: World J Gastroenterol – volume: 88 start-page: 58 year: 2016 end-page: 61 ident: bib0065 article-title: Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients publication-title: J Clin Virol – volume: 44 start-page: 856 year: 2016 end-page: 865 ident: bib0030 article-title: The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection publication-title: Aliment Pharmacol Ther – volume: 66 start-page: 153 year: 2017 end-page: 194 ident: bib0080 article-title: EASL recommendations on treatment of hepatitis C publication-title: J Hepatol – volume: 136 start-page: 37 year: 2016 end-page: 44 ident: bib0050 article-title: Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis publication-title: Antivir Res – volume: 12 start-page: 489 year: 2014 ident: bib0040 article-title: Defining ‘elderly’ in clinical practice guidelines for pharmacotherapy publication-title: Pharm Pract – volume: 64 start-page: 386 year: 2016 end-page: 393 ident: bib0140 article-title: Patient reported outcomes of elderly adults with chronic hepatitis C treated with interferon and ribavirin free regimens publication-title: J Am Geriatr Soc – volume: 8 start-page: 591 year: 2016 end-page: 597 ident: bib0110 article-title: Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting publication-title: Clin Econ Outcomes Res – volume: 95 start-page: e2482 year: 2016 ident: bib0090 article-title: Predictors of inpatient mortality and resource utilization for the elderly patients with chronic hepatitis C (CH-C) in the United States publication-title: Medicine – volume: 43 start-page: 674 year: 2016 end-page: 696 ident: bib0130 article-title: Review article: safety and tolerability of direct acting antiviral agents in the new era of hepatitis C therapy publication-title: Aliment Pharmacol Ther – volume: 41 start-page: 689 year: 2009 end-page: 699 ident: bib0010 article-title: Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy publication-title: Scand J Infect Dis – volume: 24 start-page: 174 year: 2017 end-page: 175 ident: bib0085 article-title: Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: a turning-off effect of liver inflammation? publication-title: J Viral Hepat – volume: 23 start-page: 342 year: 2017 end-page: 343 ident: bib0115 article-title: HCV and diabetes: towards a ‘sustained’ glycaemic improvement after treatment with DAAs? publication-title: Clin Microbiol Infect – volume: 60 start-page: E1 year: 2012 end-page: E25 ident: bib0025 article-title: Guiding principles for the care of older adults with multimorbidity: an approach for clinicians publication-title: J Am Geriatr Soc – volume: 66 start-page: 521 year: 2017 end-page: 527 ident: bib0055 article-title: Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B publication-title: J Hepatol – year: 2016 ident: bib0005 article-title: Annual Epidemiological Report 2016—Hepatitis B [Internet] – volume: 48 start-page: 835 year: 2008 end-page: 847 ident: bib0075 article-title: Non-invasive evaluation of liver fibrosis using transient elastography publication-title: J Hepatol – volume: 6 start-page: 149 year: 2006 end-page: 158 ident: bib0070 article-title: Reviewing the definition of elderly publication-title: Geriatr Gerontol Int – volume: 11 start-page: e0157832 year: 2016 ident: bib0135 article-title: Treatment of chronic hepatitis C in the aged—does it impact life expectancy? A decision analysis publication-title: PLoS One – volume: 95 start-page: e5143 year: 2016 ident: bib0100 article-title: Epidemiological burden estimates for pathologies with a nonconstant risk: an application to HCV in Italy according to age, Metavir score, and genotype: a systematic review and meta-analysis publication-title: Medicine – volume: 146 start-page: 1176 year: 2014 end-page: 1192 ident: bib0035 article-title: New hepatitis C therapies: the toolbox, strategies, and challenges publication-title: Gastroenterology – volume: 14 start-page: 1821 year: 2016 end-page: 1830 ident: bib0125 article-title: Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis publication-title: Clin Gastroenterol Hepatol – volume: 63 start-page: 2065 year: 2016 end-page: 2066 ident: bib0120 article-title: Hypoglycemia in a diabetic patient during hepatitis C therapy publication-title: Hepatology (Baltimore, Md) – volume: 60 start-page: E1 year: 2012 ident: 10.1016/j.dld.2017.05.019_bib0025 article-title: Guiding principles for the care of older adults with multimorbidity: an approach for clinicians publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.2012.04188.x – volume: 23 start-page: 342 issue: 5 year: 2017 ident: 10.1016/j.dld.2017.05.019_bib0115 article-title: HCV and diabetes: towards a ‘sustained’ glycaemic improvement after treatment with DAAs? publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2016.09.021 – volume: 10 start-page: 415 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0020 article-title: Hepatitis C virus as a systemic disease: reaching beyond the liver publication-title: Hepatol Int doi: 10.1007/s12072-015-9684-3 – volume: 66 start-page: 153 issue: 1 year: 2017 ident: 10.1016/j.dld.2017.05.019_bib0080 article-title: EASL recommendations on treatment of hepatitis C publication-title: J Hepatol doi: 10.1016/j.jhep.2016.09.001 – volume: 89 start-page: 291 year: 2017 ident: 10.1016/j.dld.2017.05.019_bib0105 article-title: Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: tail of a cohort infected in past decades publication-title: J Med Virol doi: 10.1002/jmv.24635 – volume: 8 start-page: 591 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0110 article-title: Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting publication-title: Clin Econ Outcomes Res doi: 10.2147/CEOR.S108288 – volume: 11 start-page: e0157832 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0135 article-title: Treatment of chronic hepatitis C in the aged—does it impact life expectancy? A decision analysis publication-title: PLoS One doi: 10.1371/journal.pone.0157832 – volume: 136 start-page: 37 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0050 article-title: Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis publication-title: Antivir Res doi: 10.1016/j.antiviral.2016.10.012 – volume: 66 start-page: 521 year: 2017 ident: 10.1016/j.dld.2017.05.019_bib0055 article-title: Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B publication-title: J Hepatol doi: 10.1016/j.jhep.2016.11.012 – volume: 146 start-page: 1176 year: 2014 ident: 10.1016/j.dld.2017.05.019_bib0035 article-title: New hepatitis C therapies: the toolbox, strategies, and challenges publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.03.003 – volume: 52 start-page: 518 year: 2010 ident: 10.1016/j.dld.2017.05.019_bib0095 article-title: Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection publication-title: Hepatology doi: 10.1002/hep.23691 – volume: 41 start-page: 689 year: 2009 ident: 10.1016/j.dld.2017.05.019_bib0010 article-title: Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy publication-title: Scand J Infect Dis doi: 10.1080/00365540903095358 – volume: 88 start-page: 58 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0065 article-title: Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients publication-title: J Clin Virol doi: 10.1016/j.jcv.2017.01.003 – volume: 21 start-page: 7412 year: 2015 ident: 10.1016/j.dld.2017.05.019_bib0015 article-title: Hepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimens publication-title: World J Gastroenterol doi: 10.3748/wjg.v21.i24.7412 – volume: 6 start-page: 149 year: 2006 ident: 10.1016/j.dld.2017.05.019_bib0070 article-title: Reviewing the definition of elderly publication-title: Geriatr Gerontol Int doi: 10.1111/j.1447-0594.2006.00341.x – volume: 63 start-page: 2065 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0120 article-title: Hypoglycemia in a diabetic patient during hepatitis C therapy publication-title: Hepatology (Baltimore, Md) doi: 10.1002/hep.28137 – volume: 12 start-page: 489 year: 2014 ident: 10.1016/j.dld.2017.05.019_bib0040 article-title: Defining ‘elderly’ in clinical practice guidelines for pharmacotherapy publication-title: Pharm Pract – volume: 48 start-page: 835 year: 2008 ident: 10.1016/j.dld.2017.05.019_bib0075 article-title: Non-invasive evaluation of liver fibrosis using transient elastography publication-title: J Hepatol doi: 10.1016/j.jhep.2008.02.008 – volume: 43 start-page: 674 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0130 article-title: Review article: safety and tolerability of direct acting antiviral agents in the new era of hepatitis C therapy publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13514 – year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0005 – volume: 24 start-page: 454 issue: 6 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0060 article-title: Safety and efficacy of direct acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older publication-title: J Viral Hepat doi: 10.1111/jvh.12663 – volume: 95 start-page: e2482 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0090 article-title: Predictors of inpatient mortality and resource utilization for the elderly patients with chronic hepatitis C (CH-C) in the United States publication-title: Medicine doi: 10.1097/MD.0000000000002482 – volume: 64 start-page: 386 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0140 article-title: Patient reported outcomes of elderly adults with chronic hepatitis C treated with interferon and ribavirin free regimens publication-title: J Am Geriatr Soc doi: 10.1111/jgs.13928 – volume: 24 start-page: 174 year: 2017 ident: 10.1016/j.dld.2017.05.019_bib0085 article-title: Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: a turning-off effect of liver inflammation? publication-title: J Viral Hepat doi: 10.1111/jvh.12636 – volume: 37 start-page: 653 issue: 5 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0045 article-title: Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype-1 elderly cirrhotic patients: a real life study publication-title: Liver Int doi: 10.1111/liv.13288 – volume: 14 start-page: 1821 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0125 article-title: Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2016.07.001 – volume: 44 start-page: 856 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0030 article-title: The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13769 – volume: 95 start-page: e5143 year: 2016 ident: 10.1016/j.dld.2017.05.019_bib0100 article-title: Epidemiological burden estimates for pathologies with a nonconstant risk: an application to HCV in Italy according to age, Metavir score, and genotype: a systematic review and meta-analysis publication-title: Medicine doi: 10.1097/MD.0000000000005143 |
| SSID | ssj0021650 |
| Score | 2.216546 |
| Snippet | Direct antiviral agents (DAAs) for chronic hepatitis C showed great effectiveness and good safety profile. So far, few data are available about their use in... Abstract Background direct antiviral agents (DAAs) for chronic hepatitis C showed great effectiveness and good safety profile. So far, few data are available... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1036 |
| SubjectTerms | Aged Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral treatment Benzimidazoles - therapeutic use Chronic hepatitis C Drug Interactions Drug Therapy, Combination Female Fluorenes - therapeutic use Gastroenterology and Hepatology HCV Hepacivirus Hepatitis C, Chronic - drug therapy Humans Imidazoles - therapeutic use Italy Logistic Models Male Retrospective Studies Ribavirin - therapeutic use Simeprevir - therapeutic use Sofosbuvir - therapeutic use Sustained Virologic Response |
| Title | The elderly and direct antiviral agents: Constraint or challenge? |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1590865817308964 https://www.clinicalkey.es/playcontent/1-s2.0-S1590865817308964 https://dx.doi.org/10.1016/j.dld.2017.05.019 https://www.ncbi.nlm.nih.gov/pubmed/28651903 https://www.proquest.com/docview/1914289581 |
| Volume | 49 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1dS-QwcBAP5F4Oz4-71XOJcPgg9LZJ0zbxRRZxWT30RQXfQtqm4LHXld31wRd_-82k6YL4cSD0oS2TTjKdzEw7XwA_c6mLOhV1ZCnFRyJUZKWgCADLbZ7KovLFqi8us_GNPL9Nb1fgpMuFobDKIPtbme6ldbgzCNQc3N_dDa44tetGBcqRSZXOqCaolDnVz__1tAzzEDzzXVoJOCLozrPpY7yqCRUL5aF4p35LN71le3odNFqHL8F4ZMN2fl9hxTUbsDls8MP57yM7YD6c0_8n34C1i-A134Qh8gJz1I578shsU7F2zXhKrSNm-ERLCVbzI0btO33TiAWbzljZNVo53oKb0en1yTgKrROiUqZqEWXCidrmXGTO5o47bSslXVwnmfejZtomrshKldgqcXWhbFLVSpZFpVTlkGTJNqw208Z9B5agQaeETYXOY2lLrlHF52mp8Si5qOMexB3RTBnqitNMJ6YLIPtjkM6G6Gzi1CCde3C4HHLfFtV4D1h0b8J02aIo3wyK_PcG5a8NcvOwQ-eGm7kwsXnBRT2Qy5HPGPF_CPc7JjG4QcnrYhs3fUBEmoraacTQg28t9ywXTWnBaJElOx9Duguf6aoNefsBq4vZg9tDG2lR9P0m6MOn4dnv8eU_R78NTg |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1da9sw8OhS2PpStmYf6b40GHsYmFiybEt7GaGsJEuTl7XQNyHbMnRkTknSh_z73slyYGzNYOAHY-t88vl0d_J9AXzMpS7qVNSRpRQfiaMiKwVFAFhu81QWlS9WPZtn4yv5_Tq9PoCzLheGwiqD7G9lupfW4cowUHN4e3Mz_MGpXTcqUI5MqnQmH8EhVadCZj8cTabj-W7fxTPfqJXGRwTQOTd9mFe1oHqhPNTv1A-pp4fMT6-Gzp_CcbAf2aid4jM4cM0J9EcN7p1_bdkn5iM6_a_yE3g8C47zPoyQHZijjtyLLbNNxdrXxlPqHrHCJ1rKsVp_YdTB0_eN2LDlipVdr5Wvz-Hq_Nvl2TgK3ROiUqZqE2XCidrmXGTO5o47bSslXVwnmXelZtomrshKldgqcXWhbFLVSpZFpVTlkGTJC-g1y8a9ApagTaeETYXOY2lLrlHL52mp8Si5qOMBxB3RTBlKi9NMF6aLIftpkM6G6Gzi1CCdB_B5B3Lb1tXYN1h0X8J0CaMo4gxK_X1A-d-A3Dos0rXhZi1MbP5gpAHIHeRvvPgvhB86JjG4RsnxYhu3vENEmuraacQwgJct9-xemjKD0ShLTv8P6Xt4Mr6cXZiLyXz6Go7oThsB9wZ6m9Wde4sm06Z4F5bEPX8jD_8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+elderly+and+direct+antiviral+agents%3A+Constraint+or+challenge%3F&rft.jtitle=Digestive+and+liver+disease&rft.au=Fabrizio%2C+Claudia&rft.au=Saracino%2C+Annalisa&rft.au=Scudeller%2C+Luigia&rft.au=Milano%2C+Eugenio&rft.date=2017-09-01&rft.issn=1878-3562&rft.eissn=1878-3562&rft.volume=49&rft.issue=9&rft.spage=1036&rft_id=info:doi/10.1016%2Fj.dld.2017.05.019&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1590-8658&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1590-8658&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1590-8658&client=summon |